HOW CAN WE HELP YOU? Call 1-800-TRY-CHOP
In This Section
Lindsey A. George, MD
Tenure Assistant Professor of Pediatrics, Perelman School of Medicine, University of Pennsylvania
Dr. George's basic and clinical research interests are in the development of novel therapeutics for hemophilia. Her basic science laboratory studies the molecular basis of coagulation, and she is the principal investigator of ongoing hemophilia A and B gene therapy trials.
Bio
Dr. George's basic and clinical research interests are in the development of novel therapeutics for hemophilia. Her basic science laboratory studies the molecular basis of coagulation with the goal of exploiting the biochemical basis of blood clotting for therapeutic translation. She is the principal investigator of ongoing hemophilia A and B gene therapy trials.
Education and Training
BS, Cornell University, 2004
MD, University at Buffalo School of Medicine, 2008
Pediatric Resident, Weill Cornell Medical College 2008-2011
Pediatric Chief Resident, Weill Cornell Medical College 2011-2012
Pediatric Hematology/Oncology fellowship, Children's Hospital of Philadelphia 2012-2015
Titles and Academic Titles
Tenure Assistant Professor of Pediatrics, Perelman School of Medicine, University of Pennsylvania
Member, Perelman Center for Cellular and Molecular Therapeutics
Attending Physician, Division of Hematology, Children's Hospital of Philadelphia
Professional Memberships
International Society of Thrombosis and Haemostasis World Federation of Hemophilia, 2013-
World Federation of Hemophilia, 2017-
American Society of Hematology, 2010-
American Society of Gene and Cell Therapy, 2015-
Hemostasis and Thrombosis Research Society, 2015-
Professional Awards
2017 Eberhard Mammen Young Investigator Award for Excellence in Thrombosis and Hemostasis, San Diego, CA
2018 Professor Heimburger Award in Hemostasis, Marburg, Germany
2019 National Top 10 Clinical/Translational Research Award, Clinical Research Forum, Washington, D.C.
2019 Scholar Award of the National Blood Foundation, Washington, D.C.
Publication Highlights
Pubmed:
Doshi BS, Raffini LJ, George LA. Combined anti-CD20 and mTOR inhibition with factor VIII for immune tolerance induction in hemophilia A patients with refractory inhibitors. J Thromb Haemost. 2020 Apr; In Press, 2020
Wilhelm AR, Parsons N, Davidson RJ, Camire RM, George LA. In Vivo Hemostatic Significance of Activated Protein C in Factor VIIIa Regulation. Blood. 2019 Nov; 134 (Supplement 1): 93
Ragni MV, George LA. The National Blueprint for Future Factor VIII Inhibitor Clinical Trials: NHLBI State of the Science (SOS) Workshop on Factor VIII Inhibitors. Haemophilia. 2019 Jan; 25(4): 581-589. PubMed PMID: 31329364
Samelson-Jones BJ, Finn JD, George LA, Camire RM, Arruda VR1. Hyperactivity of factor IX Padua (R338L) depends on factor VIIIa cofactor activity. JCI Insight. 2019 Jan; 5(14). PubMed PMID: 31219805
George LA, Sullivan SK, Giermasz A, Rasko JEJ, Samelson-Jones BJ, Ducore J, Cuker A, Sullivan LM, Majumdar S, Teitel J, McGuinn CE, Ragni MV, Luk AY, Hui D, Wright JF, Chen Y, Liu Y, Wachtel K, Winters A, Tiefenbacher S, Arruda VR, van der Loo JCM, Zelenaia O, Takefman D, Carr ME, Couto LB, Anguela XM, High KA. Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant. N Engl J Med. 2017 Dec; 377(23):2215-2227. PMID: 29211678